title: Acute myelogenous leukemia in Down's syndrome: report of a single pediatric institution using a BFM treatment strategy.
abstract: Between July 1990 and December 1995, 111 new consecutive pediatric patients with acute myelogenous leukemia (AML) have been treated in our institution. Eleven of them (9.9%) had Down's syndrome (DS), 6 boys and 5 girls. The median age was 22.5 (range 10-40) months. FAB subtypes were the following: M7: 6, M4: 3, and M0: 2. Five of them had previously had myelodysplasia and in 3, all FAB M7, myelofibrosis was detected. This population was treated with two consecutive protocols. Nine patients were included in the AML-HPG-90 protocol and 2 patients in the AML-HPG-95 study, respectively. However, all DS patients in this series received the same treatment. Eight patients achieved complete remission: two patients received two cycles of intensification with high dose (HD) ara-C, and 1 patient, only one cycle; the other 5 were prevented from receiving such therapy because of unacceptable toxicity or death. At 45 months, event-free survival and overall survival estimates were 0.30, S.E. 0.16. Mortality was remarkably high. All deaths (7) were associated with sepsis (5) or pulmonary infection (2). Three deaths occurred before achieving complete remission, 3 patients died during the consolidation phase and 1 died whilst off treatment. No one presented leukemic relapse. We conclude that this AML-BFM treatment strategy is highly toxic to children with DS and AML in our setting. Efforts will be made to improve clinical support and to administer less intensive therapy to this particular pediatric AML subgroup, which, in fact, has a better prognosis than the same non-trisomic population.
authors.affiliation: Department of Hematology/Oncology, Hospital de Pediatria SAMIC Professor Dr.J.P. Garrahan, Buenos Aires, Argentina. garrahan@giga.com.ar
authors.forename: P
authors.initials: P
authors.lastname: Zubizarreta
authors.forename: M S
authors.initials: MS
authors.lastname: Felice
authors.forename: E
authors.initials: E
authors.lastname: Alfaro
authors.forename: L
authors.initials: L
authors.lastname: Fraquelli
authors.forename: S
authors.initials: S
authors.lastname: Casak
authors.forename: R
authors.initials: R
authors.lastname: Quinteros
authors.forename: A
authors.initials: A
authors.lastname: Cygler
authors.forename: M
authors.initials: M
authors.lastname: Gallego
authors.forename: L E
authors.initials: LE
authors.lastname: Pérez
authors.forename: F
authors.initials: F
authors.lastname: Sackmann-Muriel
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001118:Argentina; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage / Q000633:toxicity; D004314:Down Syndrome / Q000150:complications*; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000633:toxicity; D007223:Infant; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015703:Antigens, CD; D003561:Cytarabine; D005047:Etoposide; D015255:Idarubicin